Skip to Main Content
Collection

DNA Repair and Nucleic Acids Therapeutics Collection

Guest Editor: Robert W. Sobol, PhD, Dean’s Professor of Cancer Research in the Department of Pathology and Laboratory Medicine at the Warren Alpert Medical School, Brown University and the Associate Director for Basic Research at the Legorreta Cancer Center at Brown University, Providence, RI, USA.
  • Share

Maintenance of the genome is dependent on error-free DNA replication, RNA transcription and telomere stability and is accomplished by a complex network of DNA repair and response mechanisms able to respond to DNA insults from both endogenous and exogenous genotoxins. This network of protein machines, engaged and activated in response to numerous types of genome damage, is referred to as the DNA damage response (DDR). 

Research over the past few decades has focused on a deeper understanding of DNA repair and DNA damage response mechanisms and clarification of the functional overlap between DNA repair pathways, replication, and cancer specific genotypes. In this special collection from NAR Cancer, we have collated a series of new review articles that focus on some of the most pressing issues in cancer biology related to current and potentially future therapeutics targeting the DDR. Additionally, we have collected some previously published articles that speak to the importance of this topic as well. 

Editorial

Editorial: DNA repair and nucleic acid therapeutics in cancer
Robert W Sobol
NAR Cancer, Volume 5, Issue 3, September 2023, zcad044, https://doi.org/10.1093/narcan/zcad044
NAR Cancer is pleased to publish a collection of articles [ https://dbpia.nl.go.kr/narcancer/pages/dna-repair-and-nucleic-acids-therapeutics ] highlighting the breakthroughs and promise of targeting DNA Repair and DNA damage response mechanisms centered around the theme of ‘ DNA Repair and ...

Latest Articles on this Topic

Roles of trans-lesion synthesis (TLS) DNA polymerases in tumorigenesis and cancer therapy
Jay Anand and others
NAR Cancer, Volume 5, Issue 1, March 2023, zcad005, https://doi.org/10.1093/narcan/zcad005
DNA damage tolerance and mutagenesis are hallmarks and enabling characteristics of neoplastic cells that drive tumorigenesis and allow cancer cells to resist therapy. The ‘Y-family’ trans-lesion synthesis (TLS) DNA polymerases enable cells to replicate damaged genomes, thereby conferring DNA damage ...
The dynamic process of covalent and non-covalent PARylation in the maintenance of genome integrity: a focus on PARP inhibitors
Adèle Beneyton and others
NAR Cancer, Volume 5, Issue 3, September 2023, zcad043, https://doi.org/10.1093/narcan/zcad043
Poly(ADP-ribosylation) (PARylation) by poly(ADP-ribose) polymerases (PARPs) is a highly regulated process that consists of the covalent addition of polymers of ADP-ribose (PAR) through post-translational modifications of substrate proteins or non-covalent interactions with PAR via PAR binding ...
Replication DNA polymerases, genome instability and cancer therapies
Juliet D Strauss and Zachary F Pursell
NAR Cancer, Volume 5, Issue 3, September 2023, zcad033, https://doi.org/10.1093/narcan/zcad033
It has been over a decade since the initial identification of exonuclease domain mutations in the genes encoding the catalytic subunits of replication DNA polymerases ϵ and δ ( POLE and POLD1 ) in tumors from highly mutated endometrial and colorectal cancers. Interest in studying POLE and POLD1 has ...
R-loops, type I topoisomerases and cancer
Sourav Saha and Yves Pommier
NAR Cancer, Volume 5, Issue 1, March 2023, zcad013, https://doi.org/10.1093/narcan/zcad013
R-loops are abundant and dynamic structures ubiquitously present in human cells both in the nuclear and mitochondrial genomes. They form in cis in the wake of transcription complexes and in trans apart from transcription complexes. In this review, we focus on the relationship between R-loops and ...
Molecular mechanisms protecting centromeres from self-sabotage and implications for cancer therapy
Rim Nassar and others
NAR Cancer, Volume 5, Issue 2, June 2023, zcad019, https://doi.org/10.1093/narcan/zcad019
Centromeres play a crucial role in DNA segregation by mediating the cohesion and separation of sister chromatids during cell division. Centromere dysfunction, breakage or compromised centromeric integrity can generate aneuploidies and chromosomal instability, which are cellular features associated ...
APE2: catalytic function and synthetic lethality draw attention as a cancer therapy target
Anne McMahon and others
NAR Cancer, Volume 5, Issue 1, March 2023, zcad006, https://doi.org/10.1093/narcan/zcad006
AP endonuclease 2 (APE2, APEX2 or APN2) is an emerging critical protein involved in genome and epigenome integrity. Whereas its catalytic function as a nuclease in DNA repair is widely accepted, recent studies have elucidated the function and mechanism of APE2 in the immune response and DNA damage ...
Current proteomics methods applicable to dissecting the DNA damage response
Monita Muralidharan and others
NAR Cancer, Volume 5, Issue 2, June 2023, zcad020, https://doi.org/10.1093/narcan/zcad020
The DNA damage response (DDR) entails reorganization of proteins and protein complexes involved in DNA repair. The coordinated regulation of these proteomic changes maintains genome stability. Traditionally, regulators and mediators of DDR have been investigated individually. However, recent ...
Mono-ADP-ribosylation by PARP10 and PARP14 in genome stability
Ashna Dhoonmoon and Claudia M Nicolae
NAR Cancer, Volume 5, Issue 1, March 2023, zcad009, https://doi.org/10.1093/narcan/zcad009
ADP-ribosylation is a post-translational modification involved in a variety of processes including DNA damage repair, transcriptional regulation, and cellular proliferation. Depending on the number of ADP moieties transferred to target proteins, ADP-ribosylation can be classified either as ...
DNA mismatch repair in cancer immunotherapy
Junhong Guan and Guo-Min Li
NAR Cancer, Volume 5, Issue 3, September 2023, zcad031, https://doi.org/10.1093/narcan/zcad031
Tumors defective in DNA mismatch repair (dMMR) exhibit microsatellite instability (MSI). Currently, patients with dMMR tumors are benefitted from anti-PD-1/PDL1-based immune checkpoint inhibitor (ICI) therapy. Over the past several years, great progress has been made in understanding the mechanisms ...
Mechanisms of PARP1 inhibitor resistance and their implications for cancer treatment
Lindsey M Jackson and George-Lucian Moldovan
NAR Cancer, Volume 4, Issue 4, December 2022, zcac042, https://doi.org/10.1093/narcan/zcac042
The discovery of synthetic lethality as a result of the combined loss of PARP1 and BRCA has revolutionized the treatment of DNA repair-deficient cancers. With the development of PARP inhibitors, patients displaying germline or somatic mutations in BRCA1 or BRCA2 were presented with a novel ...
Recent advancements in the structural biology of human telomerase and their implications for improved design of cancer therapeutics
Griffin A Welfer and Bret D Freudenthal
NAR Cancer, Volume 5, Issue 1, March 2023, zcad010, https://doi.org/10.1093/narcan/zcad010
Telomerase is a specialized reverse transcriptase that synthesizes telomeric repeats at the ends of linear chromosomes. Telomerase is transiently expressed in germ and stem cells, but nearly all somatic cells silence it after differentiating. However, the vast majority of cancer cells reactivate ...

Related Standard Articles on this Topic

Therapeutic disruption of RAD52–ssDNA complexation via novel drug-like inhibitors
Divya S Bhat and others
NAR Cancer, Volume 5, Issue 2, June 2023, zcad018, https://doi.org/10.1093/narcan/zcad018
RAD52 protein is a coveted target for anticancer drug discovery. Similar to poly-ADP-ribose polymerase (PARP) inhibitors, pharmacological inhibition of RAD52 is synthetically lethal with defects in genome caretakers BRCA1 and BRCA2 (∼25% of breast and ovarian cancers). Emerging structure activity ...
Molecular origins of mutational spectra produced by the environmental carcinogen N-nitrosodimethylamine and SN1 chemotherapeutic agents
Amanda L Armijo and others
NAR Cancer, Volume 5, Issue 2, June 2023, zcad015, https://doi.org/10.1093/narcan/zcad015
DNA-methylating environmental carcinogens such as N -nitrosodimethylamine (NDMA) and certain alkylators used in chemotherapy form O 6 -methylguanine (m6G) as a functionally critical intermediate. NDMA is a multi-organ carcinogen found in contaminated water, polluted air, preserved foods, tobacco ...
The hereditary N363K POLE exonuclease mutant extends PPAP tumor spectrum to glioblastomas by causing DNA damage and aneuploidy in addition to increased mismatch mutagenicity
Guillaume Labrousse and others
NAR Cancer, Volume 5, Issue 2, June 2023, zcad011, https://doi.org/10.1093/narcan/zcad011
The exonuclease domain of DNA polymerases epsilon's catalytic subunit (POLE) removes misincorporated nucleotides, called proofreading. POLE-exonuclease mutations cause colorectal- and endometrial cancers with an extreme burden of single nucleotide substitutions. We recently reported that ...
Ku–DNA binding inhibitors modulate the DNA damage response in response to DNA double-strand breaks
Pamela L Mendoza-Munoz and others
NAR Cancer, Volume 5, Issue 1, March 2023, zcad003, https://doi.org/10.1093/narcan/zcad003
The DNA-dependent protein kinase (DNA-PK) plays a critical role in the DNA damage response (DDR) and non-homologous end joining (NHEJ) double-strand break (DSB) repair pathways. Consequently, DNA-PK is a validated therapeutic target for cancer treatment in certain DNA repair-deficient cancers and ...
Targeted zinc-finger repressors to the oncogenic HBZ gene inhibit adult T-cell leukemia (ATL) proliferation
Tristan A Scott and others
NAR Cancer, Volume 5, Issue 1, March 2023, zcac046, https://doi.org/10.1093/narcan/zcac046
Human T-lymphotropic virus type I (HTLV-I) infects CD4+ T-cells resulting in a latent, life-long infection in patients. Crosstalk between oncogenic viral factors results in the transformation of the host cell into an aggressive cancer, adult T-cell leukemia/lymphoma (ATL). ATL has a poor prognosis ...
ATR inhibition overcomes platinum tolerance associated with ERCC1- and p53-deficiency by inducing replication catastrophe
Joshua R Heyza and others
NAR Cancer, Volume 5, Issue 1, March 2023, zcac045, https://doi.org/10.1093/narcan/zcac045
ERCC1/XPF is a heterodimeric DNA endonuclease critical for repair of certain chemotherapeutic agents. We recently identified that ERCC1- and p53-deficient lung cancer cells are tolerant to platinum-based chemotherapy. ATR inhibition synergistically re-stored platinum sensitivity to platinum ...
Multiple-low-dose therapy: effective killing of high-grade serous ovarian cancer cells with ATR and CHK1 inhibitors
Anya Golder and others
NAR Cancer, Volume 4, Issue 4, December 2022, zcac036, https://doi.org/10.1093/narcan/zcac036
High-grade serous ovarian cancer (HGSOC) is an aggressive disease that typically develops drug resistance, thus novel biomarker-driven strategies are required. Targeted therapy focuses on synthetic lethality—pioneered by PARP inhibition of BRCA1/2 -mutant disease. Subsequently, targeting the DNA ...
Escape from G1 arrest during acute MEK inhibition drives the acquisition of drug resistance
Prasanna Channathodiyil and others
NAR Cancer, Volume 4, Issue 4, December 2022, zcac032, https://doi.org/10.1093/narcan/zcac032
Mutations and gene amplifications that confer drug resistance emerge frequently during chemotherapy, but their mechanism and timing are poorly understood. Here, we investigate BRAF V600E amplification events that underlie resistance to the MEK inhibitor selumetinib (AZD6244/ARRY-142886) in COLO205 ...
High-throughput screen to identify compounds that prevent or target telomere loss in human cancer cells
Chris Wilson and John P Murnane
NAR Cancer, Volume 4, Issue 4, December 2022, zcac029, https://doi.org/10.1093/narcan/zcac029
Chromosome instability (CIN) is an early step in carcinogenesis that promotes tumor cell progression and resistance to therapy. Using plasmids integrated adjacent to telomeres, we have previously demonstrated that the sensitivity of subtelomeric regions to DNA double-strand breaks (DSBs) ...
The DNA repair function of BCL11A suppresses senescence and promotes continued proliferation of triple-negative breast cancer cells
Elise Vickridge and others
NAR Cancer, Volume 4, Issue 4, December 2022, zcac028, https://doi.org/10.1093/narcan/zcac028
We identified the BCL11A protein in a proximity-dependent biotinylation screen performed with the DNA glycosylase NTHL1. In vitro , DNA repair assays demonstrate that both BCL11A and a small recombinant BCL11A 160–520 protein that is devoid of DNA binding and transcription regulatory domains can ...
High replication stress and limited Rad51-mediated DNA repair capacity, but not oxidative stress, underlie oligodendrocyte precursor cell radiosensitivity
N Daniel Berger and others
NAR Cancer, Volume 4, Issue 2, June 2022, zcac012, https://doi.org/10.1093/narcan/zcac012
Cranial irradiation is part of the standard of care for treating pediatric brain tumors. However, ionizing radiation can trigger serious long-term neurologic sequelae, including oligodendrocyte and brain white matter loss enabling neurocognitive decline in children surviving brain cancer. Oxidative ...
Mouse model and human patient data reveal critical roles for Pten and p53 in suppressing POLE mutant tumor development
Vivian S Park and others
NAR Cancer, Volume 4, Issue 1, March 2022, zcac004, https://doi.org/10.1093/narcan/zcac004
Mutations in the exonuclease domain of POLE are associated with tumors harboring very high mutation burdens. The mechanisms linking this significant mutation accumulation and tumor development remain poorly understood. Pole +/P286R ; Trp53 +/– mice showed accelerated cancer mortality compared to ...
NAD+ bioavailability mediates PARG inhibition-induced replication arrest, intra S-phase checkpoint and apoptosis in glioma stem cells
Jianfeng Li and others
NAR Cancer, Volume 3, Issue 4, December 2021, zcab044, https://doi.org/10.1093/narcan/zcab044
Elevated expression of the DNA damage response proteins PARP1 and poly(ADP-ribose) glycohydrolase (PARG) in glioma stem cells (GSCs) suggests that glioma may be a unique target for PARG inhibitors (PARGi). While PARGi-induced cell death is achieved when combined with ionizing radiation, as a single ...
Genome instability and pressure on non-homologous end joining drives chemotherapy resistance via a DNA repair crisis switch in triple negative breast cancer
Adrian P Wiegmans and others
NAR Cancer, Volume 3, Issue 2, June 2021, zcab022, https://doi.org/10.1093/narcan/zcab022
Chemotherapy is used as a standard-of-care against cancers that display high levels of inherent genome instability. Chemotherapy induces DNA damage and intensifies pressure on the DNA repair pathways that can lead to deregulation. There is an urgent clinical need to be able to track the emergence ...
Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity
Sophia Gayle and others
NAR Cancer, Volume 3, Issue 2, June 2021, zcab021, https://doi.org/10.1093/narcan/zcab021
Topoisomerase inhibitors are potent DNA damaging agents which are widely used in oncology, and they demonstrate robust synergistic tumor cell killing in combination with DNA repair inhibitors, including poly(ADP)-ribose polymerase (PARP) inhibitors. However, their use has been severely limited by ...
Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors
Amrita Sule and others
NAR Cancer, Volume 3, Issue 2, June 2021, zcab018, https://doi.org/10.1093/narcan/zcab018
Mutations in the isocitrate dehydrogenase-1 and -2 (IDH1/2) genes were first identified in glioma and acute myeloid leukemia (AML), and subsequently found in multiple other tumor types. These neomorphic mutations convert the normal product of enzyme, α-ketoglutarate (αKG), to the oncometabolite ...
Transgene codon usage drives viral fitness and therapeutic efficacy in oncolytic adenoviruses
Estela Núñez-Manchón and others
NAR Cancer, Volume 3, Issue 2, June 2021, zcab015, https://doi.org/10.1093/narcan/zcab015
Arming oncolytic adenoviruses with therapeutic transgenes is a well-established strategy for multimodal tumour attack. However, this strategy sometimes leads to unexpected attenuated viral replication and a loss of oncolytic effects, preventing these viruses from reaching the clinic. Previous work ...
Inhibition of tryptophan 2,3-dioxygenase impairs DNA damage tolerance and repair in glioma cells
Megan R Reed and others
NAR Cancer, Volume 3, Issue 2, June 2021, zcab014, https://doi.org/10.1093/narcan/zcab014
Expression of tryptophan 2,3-dioxygenase (TDO) is a determinant of malignancy in gliomas through kynurenine (KYN) signaling. We report that inhibition of TDO activity attenuated recovery from replication stress and increased the genotoxic effects of bis-chloroethylnitrosourea (BCNU). Activation of ...
Ubiquitination-mediated degradation of TRDMT1 regulates homologous recombination and therapeutic response
Xiaolan Zhu and others
NAR Cancer, Volume 3, Issue 1, March 2021, zcab010, https://doi.org/10.1093/narcan/zcab010
The RNA methyltransferase TRDMT1 has recently emerged as a key regulator of homologous recombination (HR) in the transcribed regions of the genome, but how it is regulated and its relevance in cancer remain unknown. Here, we identified that TRDMT1 is poly-ubiquitinated at K251 by the E3 ligase ...
The DNA damage inducible lncRNA SCAT7 regulates genomic integrity and topoisomerase 1 turnover in lung adenocarcinoma
Luisa Statello and others
NAR Cancer, Volume 3, Issue 1, March 2021, zcab002, https://doi.org/10.1093/narcan/zcab002
Despite the rapid improvements in unveiling the importance of lncRNAs in all aspects of cancer biology, there is still a void in mechanistic understanding of their role in the DNA damage response. Here we explored the potential role of the oncogenic lncRNA SCAT7 (ELF3-AS1) in the maintenance of ...
Tracking telomere fusions through crisis reveals conflict between DNA transcription and the DNA damage response
Kate Liddiard and others
NAR Cancer, Volume 3, Issue 1, March 2021, zcaa044, https://doi.org/10.1093/narcan/zcaa044
Identifying attributes that distinguish pre-malignant from senescent cells provides opportunities for targeted disease eradication and revival of anti-tumour immunity. We modelled a telomere-driven crisis in four human fibroblast lines, sampling at multiple time points to delineate genomic ...
The HelQ human DNA repair helicase utilizes a PWI-like domain for DNA loading through interaction with RPA, triggering DNA unwinding by the HelQ helicase core
Tabitha Jenkins and others
NAR Cancer, Volume 3, Issue 1, March 2021, zcaa043, https://doi.org/10.1093/narcan/zcaa043
Genome instability is a characteristic enabling factor for carcinogenesis. HelQ helicase is a component of human DNA maintenance systems that prevent or reverse genome instability arising during DNA replication. Here, we provide details of the molecular mechanisms that underpin HelQ function—its ...
Dual inhibition of DNA-PK and DNA polymerase theta overcomes radiation resistance induced by p53 deficiency
Rashmi J Kumar and others
NAR Cancer, Volume 2, Issue 4, December 2020, zcaa038, https://doi.org/10.1093/narcan/zcaa038
TP53 deficiency in cancer is associated with poor patient outcomes and resistance to DNA damaging therapies. However, the mechanisms underlying treatment resistance in p53-deficient cells remain poorly characterized. Using live cell imaging of DNA double-strand breaks (DSBs) and cell cycle state ...
APOBEC3 enzymes mediate efficacy of cisplatin and are epistatic with base excision repair and mismatch repair in platinum response
Kayla L Conner and others
NAR Cancer, Volume 2, Issue 4, December 2020, zcaa033, https://doi.org/10.1093/narcan/zcaa033
Identifying the mechanisms mediating cisplatin response is essential for improving patient response. Previous research has identified base excision repair (BER) and mismatch repair (MMR) activity in sensitizing cells to cisplatin. Cisplatin forms DNA adducts including interstrand cross-links (ICLs) ...
The chemotherapeutic agent CX-5461 irreversibly blocks RNA polymerase I initiation and promoter release to cause nucleolar disruption, DNA damage and cell inviability
Jean-Clément Mars and others
NAR Cancer, Volume 2, Issue 4, December 2020, zcaa032, https://doi.org/10.1093/narcan/zcaa032
In the search for drugs to effectively treat cancer, the last 10 years have seen a resurgence of interest in targeting ribosome biogenesis. CX-5461 is a potential inhibitor of ribosomal RNA synthesis that is now showing promise in phase I trials as a chemotherapeutic agent for a range of ...
DDX5 resolves R-loops at DNA double-strand breaks to promote DNA repair and avoid chromosomal deletions
Zhenbao Yu and others
NAR Cancer, Volume 2, Issue 3, September 2020, zcaa028, https://doi.org/10.1093/narcan/zcaa028
R-loops are three-stranded structures consisting of a DNA/RNA hybrid and a displaced DNA strand. The regulatory factors required to process this fundamental genetic structure near double-strand DNA breaks (DSBs) are not well understood. We previously reported that cellular depletion of the ...
The uracil-DNA glycosylase UNG protects the fitness of normal and cancer B cells expressing AID
Shiva Safavi and others
NAR Cancer, Volume 2, Issue 3, September 2020, zcaa019, https://doi.org/10.1093/narcan/zcaa019
In B lymphocytes, the uracil N-glycosylase (UNG) excises genomic uracils made by activation-induced deaminase (AID), thus underpinning antibody gene diversification and oncogenic chromosomal translocations, but also initiating faithful DNA repair. Ung −/− mice develop B-cell lymphoma (BCL). ...
Defining the mutation signatures of DNA polymerase θ in cancer genomes
Taejoo Hwang and others
NAR Cancer, Volume 2, Issue 3, September 2020, zcaa017, https://doi.org/10.1093/narcan/zcaa017
DNA polymerase theta (POLQ)-mediated end joining (TMEJ) is a distinct pathway for mediating DNA double-strand break (DSB) repair. TMEJ is required for the viability of BRCA -mutated cancer cells. It is crucial to identify tumors that rely on POLQ activity for DSB repair, because such tumors are ...
A novel siRNA–gemcitabine construct as a potential therapeutic for treatment of pancreatic cancer
Vera Simonenko and others
NAR Cancer, Volume 2, Issue 3, September 2020, zcaa016, https://doi.org/10.1093/narcan/zcaa016
The non-nucleoside analog gemcitabine has been the standard of care for treating pancreatic cancer. The drug shows good potency in pancreatic cancer cells in vitro but, due to poor bioavailability, requires administration in large doses by infusion and this systemic exposure results in significant ...
Synthetic circular miR-21 RNA decoys enhance tumor suppressor expression and impair tumor growth in mice
Simon Müller and others
NAR Cancer, Volume 2, Issue 3, September 2020, zcaa014, https://doi.org/10.1093/narcan/zcaa014
Naturally occurring circular RNAs efficiently impair miRNA functions. Synthetic circular RNAs may thus serve as potent agents for miRNA inhibition. Their therapeutic effect critically relies on (i) the identification of optimal miRNA targets, (ii) the optimization of decoy structures and (iii) the ...
XRCC1 promotes replication restart, nascent fork degradation and mutagenic DNA repair in BRCA2-deficient cells
Bradley J Eckelmann and others
NAR Cancer, Volume 2, Issue 3, September 2020, zcaa013, https://doi.org/10.1093/narcan/zcaa013
Homologous recombination/end joining (HR/HEJ)-deficient cancers with BRCA mutations utilize alternative DNA double-strand break repair pathways, particularly alternative non-homologous end joining or microhomology-mediated end joining (alt-EJ/MMEJ) during S and G2 cell cycle phases. Depletion of ...
Clinical and functional characterization of CXCR1/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma
Chris W D Armstrong and others
NAR Cancer, Volume 2, Issue 3, September 2020, zcaa012, https://doi.org/10.1093/narcan/zcaa012
Functional impairment of the tumour suppressor PTEN is common in primary prostate cancer and has been linked to relapse post-radiotherapy (post-RT). Pre-clinical modelling supports elevated CXC chemokine signalling as a critical mediator of PTEN -depleted disease progression and therapeutic ...
Proteome dynamics analysis identifies functional roles of SDE2 and hypoxia in DNA damage response in prostate cancer cells
Ang Luo and others
NAR Cancer, Volume 2, Issue 2, June 2020, zcaa010, https://doi.org/10.1093/narcan/zcaa010
Mechanistic understanding of hypoxia-responsive signaling pathways provides important insights into oxygen- and metabolism-dependent cellular phenotypes in diseases. Using SILAC-based quantitative proteomics, we provided a quantitative map identifying over 6300 protein groups in response to hypoxia ...
Distinct roles of structure-specific endonucleases EEPD1 and Metnase in replication stress responses
Neelam Sharma and others
NAR Cancer, Volume 2, Issue 2, June 2020, zcaa008, https://doi.org/10.1093/narcan/zcaa008
Accurate DNA replication and segregation are critical for maintaining genome integrity and suppressing cancer. Metnase and EEPD1 are DNA damage response (DDR) proteins frequently dysregulated in cancer and implicated in cancer etiology and tumor response to genotoxic chemo- and radiotherapy. Here, ...
Intrinsic ATR signaling shapes DNA end resection and suppresses toxic DNA-PKcs signaling
Diego Dibitetto and others
NAR Cancer, Volume 2, Issue 2, June 2020, zcaa006, https://doi.org/10.1093/narcan/zcaa006
Most cancer cells experience oncogene-induced replication stress and, as a result, exhibit high intrinsic activation of the ATR kinase. Although cancer cells often become more dependent on ATR for survival, the precise mechanism by which ATR signaling ensures cancer cell fitness and viability ...
SMARCA4 deficiency-associated heterochromatin induces intrinsic DNA replication stress and susceptibility to ATR inhibition in lung adenocarcinoma
Kiminori Kurashima and others
NAR Cancer, Volume 2, Issue 2, June 2020, zcaa005, https://doi.org/10.1093/narcan/zcaa005
The SWI/SNF chromatin remodeling complex regulates transcription through the control of chromatin structure and is increasingly thought to play an important role in human cancer. Lung adenocarcinoma (LADC) patients frequently harbor mutations in SMARCA4, a core component of this multisubunit ...

Related Review Articles on this Topic

Quantification of radiation-induced DNA double strand break repair foci to evaluate and predict biological responses to ionizing radiation
Sébastien Penninckx and others
NAR Cancer, Volume 3, Issue 4, December 2021, zcab046, https://doi.org/10.1093/narcan/zcab046
Radiation-induced foci (RIF) are nuclear puncta visualized by immunostaining of proteins that regulate DNA double-strand break (DSB) repair after exposure to ionizing radiation. RIF are a standard metric for measuring DSB formation and repair in clinical, environmental and space radiobiology. The ...
An emerging picture of FANCJ’s role in G4 resolution to facilitate DNA replication
Robert M Brosh and Yuliang Wu
NAR Cancer, Volume 3, Issue 3, September 2021, zcab034, https://doi.org/10.1093/narcan/zcab034
A well-accepted hallmark of cancer is genomic instability, which drives tumorigenesis. Therefore, understanding the molecular and cellular defects that destabilize chromosomal integrity is paramount to cancer diagnosis, treatment and cure. DNA repair and the replication stress response are ...
Homologous recombination, cancer and the ‘RAD51 paradox’
Gabriel Matos-Rodrigues and others
NAR Cancer, Volume 3, Issue 2, June 2021, zcab016, https://doi.org/10.1093/narcan/zcab016
Genetic instability is a hallmark of cancer cells. Homologous recombination (HR) plays key roles in genome stability and variability due to its roles in DNA double-strand break and interstrand crosslink repair, and in the protection and resumption of arrested replication forks. HR deficiency leads ...
Top1-PARP1 association and beyond: from DNA topology to break repair
Srijita Paul Chowdhuri and Benu Brata Das
NAR Cancer, Volume 3, Issue 1, March 2021, zcab003, https://doi.org/10.1093/narcan/zcab003
Selective trapping of human topoisomerase 1 (Top1) on the DNA (Top1 cleavage complexes; Top1cc) by specific Top1-poisons triggers DNA breaks and cell death. Poly(ADP-ribose) polymerase 1 (PARP1) is an early nick sensor for trapped Top1cc. New mechanistic insights have been developed in recent years ...
Addressing cancer signal transduction pathways with antisense and siRNA oligonucleotides
Rudolph L Juliano
NAR Cancer, Volume 2, Issue 3, September 2020, zcaa025, https://doi.org/10.1093/narcan/zcaa025
Signal transduction pathways play key roles in the initiation, progression and dissemination of cancer. Thus, signaling molecules are attractive targets for cancer therapeutics and enormous efforts have gone into the development of small molecule inhibitors of these pathways. However, regrettably, ...
Regulation and pharmacological targeting of RAD51 in cancer
McKenzie K Grundy and others
NAR Cancer, Volume 2, Issue 3, September 2020, zcaa024, https://doi.org/10.1093/narcan/zcaa024
Regulation of homologous recombination (HR) is central for cancer prevention. However, too little HR can increase cancer incidence, whereas too much HR can drive cancer resistance to therapy. Importantly, therapeutics targeting HR deficiency have demonstrated a profound efficacy in the clinic ...
Replication protein A: a multifunctional protein with roles in DNA replication, repair and beyond
Rositsa Dueva and George Iliakis
NAR Cancer, Volume 2, Issue 3, September 2020, zcaa022, https://doi.org/10.1093/narcan/zcaa022
Single-stranded DNA (ssDNA) forms continuously during DNA replication and is an important intermediate during recombination-mediated repair of damaged DNA. Replication protein A (RPA) is the major eukaryotic ssDNA-binding protein. As such, RPA protects the transiently formed ssDNA from nucleolytic ...
Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times
Christian Bailly and others
NAR Cancer, Volume 2, Issue 1, March 2020, zcaa002, https://doi.org/10.1093/narcan/zcaa002
Monoclonal antibodies targeting programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) immune checkpoints have improved the treatments of cancers. However, not all patients equally benefit from immunotherapy. The use of cytotoxic drugs is practically inevitable to treat advanced ...
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close